Samenvatting
A prevalent eukaryotic N6-methyladensosine (m6A) post-transcriptional mark can be “erased” by the m6A demethylase FTO, which is commonly deregulated in acute myeloid leukemia (AML). In this issue of Cancer Cell, Huang et al. design small-molecule FTO inhibitors, FB23 and FB23-2, and demonstrate their potent inhibitory impact in AML models.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 540-541 |
Aantal pagina's | 2 |
Tijdschrift | Cancer Cell |
Volume | 35 |
Nummer van het tijdschrift | 4 |
DOI's | |
Status | Gepubliceerd - 15 apr. 2019 |
Extern gepubliceerd | Ja |